Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 235 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015', provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Plaque Psoriasis (Psoriasis Vulgaris) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Plaque Psoriasis (Psoriasis Vulgaris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Plaque Psoriasis (Psoriasis Vulgaris) Overview 9
Therapeutics Development 10
Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Overview 10
Pipeline Products for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis 11
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 12
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 19
Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 24
Almirall, S.A. 24
Amgen Inc. 25
Avesthagen Limited 26
Avexxin AS 27
Biocon Limited 28
Biotie Therapies Corp. 29
Can-Fite BioPharma Ltd. 30
Celltrion, Inc. 31
Circassia Pharmaceuticals plc 32
Coherus BioSciences, Inc. 33
Creabilis SA 34
Delenex Therapeutics AG 35
Dermira Inc. 36
Epirus Biopharmaceuticals, Inc. 37
Forward Pharma A/S 38
Galectin Therapeutics, Inc. 39
Genor BioPharma Co., Ltd. 40
Idera Pharmaceuticals, Inc. 41
Invion Limited 42
Johnson & Johnson 43
Kadmon Corporation, LLC 44
Kineta, Inc. 45
Kyowa Hakko Kirin Co., Ltd. 46
LEO Pharma A/S 47
Lipidor AB 48
Mabion SA 49
Maruho Co., Ltd. 50
Momenta Pharmaceuticals, Inc. 51
Oncobiologics, Inc. 52
Pfizer Inc. 53
Promius Pharma, LLC 54
Protalix BioTherapeutics, Inc. 55
Provectus Biopharmaceuticals, Inc. 56
R-Tech Ueno, Ltd. 57
TetraLogic Pharmaceuticals 58
Therapeutic Proteins International, LLC 59
UCB S.A. 60
Valeant Pharmaceuticals International, Inc. 61
XBiotech USA, Inc. 62
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 63
Assessment by Monotherapy Products 63
Assessment by Combination Products 64
Assessment by Target 65
Assessment by Mechanism of Action 68
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 74
(betamethasone dipropionate + bexarotene) - Drug Profile 74
(calcipotriene + betamethasone dipropionate) - Drug Profile 75
(calcipotriene + betamethasone) - Drug Profile 77
adalimumab biosimilar - Drug Profile 78
adalimumab biosimilar - Drug Profile 79
adalimumab biosimilar - Drug Profile 80
adalimumab biosimilar - Drug Profile 81
adalimumab biosimilar - Drug Profile 82
adalimumab biosimilar - Drug Profile 83
adalimumab biosimilar - Drug Profile 84
adalimumab biosimilar - Drug Profile 85
adalimumab biosimilar - Drug Profile 86
adalimumab biosimilar - Drug Profile 87
AM-001 - Drug Profile 88
ASKP-1240 - Drug Profile 89
AVX-001 - Drug Profile 90
betamethasone + maxacalcitol - Drug Profile 91
bimekizumab - Drug Profile 92
brodalumab - Drug Profile 93
BTT-1023 - Drug Profile 95
calcipotriene - Drug Profile 97
CF-101 - Drug Profile 98
CIR-001 - Drug Profile 100
CT-327 - Drug Profile 101
dalazatide - Drug Profile 103
DFD-01 - Drug Profile 105
DFD-06 - Drug Profile 106
dimethyl fumarate - Drug Profile 107
DLX-105 - Drug Profile 108
DRM-02 - Drug Profile 110
etanercept biosimilar - Drug Profile 111
etanercept biosimilar - Drug Profile 112
etanercept biosimilar - Drug Profile 113
etanercept biosimilar - Drug Profile 114
etanercept biosimilar - Drug Profile 115
GK-664S - Drug Profile 116
GR-MD-02 - Drug Profile 117
guselkumab - Drug Profile 120
IDP-118 - Drug Profile 123
IMO-8400 - Drug Profile 124
infliximab biosimilar - Drug Profile 126
infliximab biosimilar - Drug Profile 128
infliximab biosimilar - Drug Profile 129
infliximab biosimilar - Drug Profile 130
infliximab biosimilar - Drug Profile 131
INV-103 - Drug Profile 132
KD-025 - Drug Profile 134
LEO-32731 - Drug Profile 136
LP-0113 - Drug Profile 137
M-801801 - Drug Profile 138
MOL-4239 - Drug Profile 139
MOL-4249 - Drug Profile 140
pefcalcitol - Drug Profile 141
PF-04965842 - Drug Profile 142
PF-06700841 - Drug Profile 143
PH-10 - Drug Profile 144
RA-18C3 - Drug Profile 146
RTU-1096 - Drug Profile 148
SHP-141 - Drug Profile 149
tofacitinib - Drug Profile 151
toreforant - Drug Profile 155
ustekinumab - Drug Profile 157
Plaque Psoriasis (Psoriasis Vulgaris) - Recent Pipeline Updates 160
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 216
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 221
Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 223
Featured News & Press Releases 223
Appendix 230
Methodology 230
Coverage 230
Secondary Research 230
Primary Research 230
Expert Panel Validation 230
Contact Us 230
Disclaimer 231

List of Tables

Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H1 2015 14
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris) - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Comparative Analysis by Late Stage Development, H1 2015 20
Comparative Analysis by Clinical Stage Development, H1 2015 21
Comparative Analysis by Early Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Products under Development by Companies, H1 2015 (Contd..3) 26
Products under Development by Companies, H1 2015 (Contd..4) 27
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H1 2015 28
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H1 2015 29
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avesthagen Limited, H1 2015 30
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H1 2015 31
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H1 2015 32
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biotie Therapies Corp., H1 2015 33
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H1 2015 34
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Celltrion, Inc., H1 2015 35
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Circassia Pharmaceuticals plc, H1 2015 36
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H1 2015 37
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Creabilis SA, H1 2015 38
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Delenex Therapeutics AG, H1 2015 39
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Dermira Inc., H1 2015 40
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 41
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H1 2015 42
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Galectin Therapeutics, Inc., H1 2015 43
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co., Ltd., H1 2015 44
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 45
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Invion Limited, H1 2015 46
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H1 2015 47
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H1 2015 48
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kineta, Inc., H1 2015 49
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 50
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H1 2015 51
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H1 2015 52
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mabion SA, H1 2015 53
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H1 2015 54
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 55
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H1 2015 56
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H1 2015 57
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H1 2015 58
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 59
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 60
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by R-Tech Ueno, Ltd., H1 2015 61
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TetraLogic Pharmaceuticals, H1 2015 62
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H1 2015 63
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H1 2015 64
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015 65
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech USA, Inc., H1 2015 66
Assessment by Monotherapy Products, H1 2015 67
Assessment by Combination Products, H1 2015 68
Number of Products by Stage and Target, H1 2015 70
Number of Products by Stage and Mechanism of Action, H1 2015 73
Number of Products by Stage and Route of Administration, H1 2015 75
Number of Products by Stage and Molecule Type, H1 2015 77
Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics - Recent Pipeline Updates, H1 2015 164
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H1 2015 220
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H1 2015 221
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H1 2015 222
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H1 2015 223
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H1 2015 224
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H1 2015 225
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H1 2015 226